BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/6/2024 5:43:14 AM | Browse: 108 | Download: 347
 |
Received |
|
2024-02-27 04:17 |
|
Peer-Review Started |
|
2024-02-27 04:17 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-04-25 07:58 |
|
Revised |
|
2024-05-06 03:47 |
|
Second Decision |
|
2024-05-28 02:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-05-28 06:00 |
|
Articles in Press |
|
2024-05-28 06:00 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-30 06:36 |
|
Publish the Manuscript Online |
|
2024-06-06 05:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Approach to loss of response to advanced therapies in inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nikil Vootukuru and Abhinav Vasudevan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abhinav Vasudevan, BMed, FRACP, Doctor, Doctor, Department of Gastroenterology and Hepatology, Eastern Health, 8 Arnold St, Box Hill 3128, Victoria, Australia. abhinav.vasudevan@monash.edu |
| Key Words |
Inflammatory bowel disease; Ulcerative colitis; Crohn; Biologics; interleukin-12 and interleukin-23 inhibitors; Alpha-beta7-integrin inhibitors; Janus kinase inhibitors; Sphingosine-1-phosphate receptor modulators |
| Core Tip |
In the setting of primary non-response (PNR) and loss of response (LOR) to alpha-beta7-integrin inhibitors and interleukin (IL)-12 and IL-23 inhibitors dose optimization is a reasonable option to capture response. For Janus kinase inhibitors dose optimization can be utilized to recapture response with LOR is less successful in the setting of PNR. The role of therapeutic drug monitoring in the setting of non-tumour necrosis factor inhibitor therapies to identify patients who require dose optimization and as a predictor for clinical remission is not yet established and this remains an area that should be addressed in the future research. |
| Publish Date |
2024-06-06 05:43 |
| Citation |
<p>Vootukuru N, Vasudevan A. Approach to loss of response to advanced therapies in inflammatory bowel disease. <i>World J Gastroenterol</i> 2024; 30(22): 2902-2919</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i22/2902.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i22.2902 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
